Cyclooxygenase-2 inhibitors: promise or peril?
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing thei...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2002-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1080/09629350290000041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553356474712064 |
|---|---|
| author | Laurel J. Mengle-Gaw Benjamin D. Schwartz |
| author_facet | Laurel J. Mengle-Gaw Benjamin D. Schwartz |
| author_sort | Laurel J. Mengle-Gaw |
| collection | DOAJ |
| description | The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise questions about the benefit/risk ratio of COX-2-specific NSAIDs compared to conventional NSAIDs. This article reviews the efficacy and safety profiles of COX-2-specific inhibitors, comparing them with conventional NSDAIDs. |
| format | Article |
| id | doaj-art-c3407f2538124e068d8d2a8fda8c1ed9 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2002-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-c3407f2538124e068d8d2a8fda8c1ed92025-02-03T05:54:17ZengWileyMediators of Inflammation0962-93511466-18612002-01-0111527528610.1080/09629350290000041Cyclooxygenase-2 inhibitors: promise or peril?Laurel J. Mengle-Gaw0Benjamin D. Schwartz1Principal and Co-Founders, The Camden Group, 19 Oak Park Drive, St. Louis, 63141, MO, USAPrincipal and Co-Founders, The Camden Group, 19 Oak Park Drive, St. Louis, 63141, MO, USAThe discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise questions about the benefit/risk ratio of COX-2-specific NSAIDs compared to conventional NSAIDs. This article reviews the efficacy and safety profiles of COX-2-specific inhibitors, comparing them with conventional NSDAIDs.http://dx.doi.org/10.1080/09629350290000041 |
| spellingShingle | Laurel J. Mengle-Gaw Benjamin D. Schwartz Cyclooxygenase-2 inhibitors: promise or peril? Mediators of Inflammation |
| title | Cyclooxygenase-2 inhibitors: promise or peril? |
| title_full | Cyclooxygenase-2 inhibitors: promise or peril? |
| title_fullStr | Cyclooxygenase-2 inhibitors: promise or peril? |
| title_full_unstemmed | Cyclooxygenase-2 inhibitors: promise or peril? |
| title_short | Cyclooxygenase-2 inhibitors: promise or peril? |
| title_sort | cyclooxygenase 2 inhibitors promise or peril |
| url | http://dx.doi.org/10.1080/09629350290000041 |
| work_keys_str_mv | AT laureljmenglegaw cyclooxygenase2inhibitorspromiseorperil AT benjamindschwartz cyclooxygenase2inhibitorspromiseorperil |